The Emmes Group
The Emmes Group is a privately held specialty CRO founded in 1977 in Rockville, MD, combining full-service clinical research with the Veridix AI-enabled eClinical platform. It serves US government agencies, public-private partnerships, and commercial biopharma clients across 90+ countries.
- Company typePrivate
- Founded1977
- HeadquartersRockville, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What The Emmes Group does
The Emmes Group is a privately held, US-based contract research organization (CRO) founded in 1977 and headquartered in Rockville, Maryland. Operating as the self-described "first specialty, tech and AI-based CRO," it delivers Phase I–IV clinical research services to US government agencies, public-private partnerships, and commercial biopharmaceutical companies across 90+ countries, with 32,000+ trial sites managed and 2,150+ trials conducted to date. The company is organized into two core operating units: Emmes (the CRO services arm) and Veridix (the technology and AI platform), with additional specialty sub-brands VaxTrials (vaccines/infectious disease) and OptymEdge (ophthalmology).
The Emmes CRO arm provides full-service clinical capabilities including biostatistics, clinical data management, clinical trial management, global regulatory affairs, pharmacovigilance, and medical monitoring, with deep specialization in vaccines and infectious diseases, ophthalmology, clinical neuroscience, rare disease, cell and gene therapy, government programs, hematology, oncology, maternal and child health, and medical devices. The Veridix platform layers proprietary technology on top of these services, including the Veridix eClinical Platform (EDC, RTSM, eCOA/ePRO, decentralized clinical trials, and a Health Navigator module), GlobalTrace for site and supply chain tracking, and a suite of named AI Agents — Biostats and Analysis Agent, Data Management Agent, Document Authoring Agent — and VERA, an AI Reporting Agent for clinical analytics. In July 2024, Emmes acquired Clinical Entity Modeling tools from health tech startup Miimansa AI as part of a multi-year strategic partnership, adding AI-powered structured entity modeling to its technology stack.
Emmes generates revenue through project-based CRO contracts awarded via a Request for Proposal (RFP) process, supplemented by what source data characterizes as recurring/subscription-style engagement. Customers include US Government Agencies, Public-Private Partnerships, and Commercial Biopharma Companies across primary verticals of Government Health Agencies and Biopharmaceutical Companies (with Specialty Biopharma as a secondary vertical). Pricing is quote-based and not publicly disclosed. The company is ISO-certified and reports 434+ peer-reviewed publications since 2016, supporting its positioning as a scientifically rigorous, government-trusted research partner now actively expanding its commercial biopharma footprint under recently appointed commercial leadership.
The Emmes Group firmographics
Firmographics- Name
- The Emmes Group
- Legal name
- The Emmes Company, LLC
- Website
- https://theemmesgroup.com
- Company type
- Private
- Founded year
- 1977
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- The Emmes Group is a privately held specialty CRO founded in 1977 in Rockville, MD, combining full-service clinical research with the Veridix AI-enabled eClinical platform. It serves US government agencies, public-private partnerships, and commercial biopharma clients across 90+ countries.
- Ownership category
- akta.pro rank
The Emmes Group industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where The Emmes Group is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Markets served
The Emmes Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- CRO Services: Emmes Group generates revenue primarily through providing Contract Research Organization (CRO) services including clinical trial management, biostatistics, data management, regulatory affairs, and pharmacovigilance. As a specialty CRO with global operations across 90+ countries, revenue is generated through project-based contracts with biopharma companies, government agencies, and public-private partnerships.
Go-to-market motion1 record
The Emmes Group product offering
Product offeringCore offering
The Emmes Group is a full-service Contract Research Organization (CRO) delivering Phase I–IV clinical trial management across 90+ countries, supported by a proprietary AI-enabled technology platform (Veridix) that provides electronic data capture, randomization and supply management, eCOA/ePRO, decentralized clinical trials, global site tracking, and AI agents for biostatistics, data management, and document authoring. Specialty therapeutic expertise is delivered through dedicated brands for vaccines/infectious disease, ophthalmology, clinical neuroscience, rare disease, cell & gene therapy, and government health programs.
Product overview
The Emmes Group operates as the industry's first specialty, tech and AI-based CRO with a platform-plus-modules architecture. The core offering consists of Emmes CRO providing full-service clinical research across multiple therapeutic specialties, supported by the Veridix eClinical Platform delivering technology solutions including EDC, RTSM, eCOA/ePRO, and Decentralized Clinical Trials. AI capabilities are embedded through Veridix AI Agents (Biostats and Analysis Agent, Data Management Agent, Document Authoring Agent) and VERA reporting. Specialty sub-brands include VaxTrials for vaccines and OptymEdge for ophthalmology. The company reports 2,150+ Phase I-IV trials conducted in 90+ countries across 32,000+ clinical trial sites.
Differentiator
Problem solved
Functional benefit
Brands
- Emmes: CRO (Contract Research Organization) providing clinical research services across multiple therapeutic areas including vaccines, ophthalmology, neuroscience, rare disease, cell & gene therapy, government, hematology, oncology, and medical devices.
- Veridix
- VaxTrials
- OptymEdge
Products and services
- Emmes CRO Clinical Research Services Full-service Contract Research Organization delivering Phase I–IV clinical trial management, biostatistics, clinical data management, global regulatory affairs, pharmacovigilance, and medical monitoring across 90+ countries with specialty expertise in vaccines, ophthalmology, neuroscience, rare disease, cell & gene therapy, oncology, hematology, maternal & child health, and medical devices.
- Veridix eClinical Platform Proprietary technology and AI-enabled eClinical platform providing electronic data capture (EDC), randomization and trial supply management (RTSM), electronic clinical outcome assessments (eCOA/ePRO), decentralized clinical trials (DCT), Health Navigator for patient engagement, GlobalTrace for site and supply tracking, AI agents for biostatistics, data management, and document authoring, and VERA analytics and reporting for clinical trial execution by sponsors and CRO teams.
- VaxTrials Specialty CRO brand dedicated to designing and running vaccine and infectious disease clinical trials for government agencies, public-private partnerships, and commercial biopharma sponsors.
- OptymEdge Specialty CRO brand dedicated to ophthalmology clinical trials, supporting sponsors with design, site management, and clinical execution for vision-related therapies.
Quantifiable outcome
- Reduced costs and time for clinical trials through AI-enabled automation of data processing
Companies that use The Emmes Group
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
The Emmes Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature6 records
The Emmes Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Miimansa AIcoreMulti-year strategic partnership with health tech startup Miimansa AI, including acquisition of Clinical Entity Modeling tools. Collaboration aims to leverage advanced AI techniques to accelerate and automate data processing in clinical trials, potentially reducing costs and time. This partnership strengthens Emmes Group's AI capabilities and positions them at the forefront of AI-enabled clinical research.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
The Emmes Group competitors and assessment
Company assessmentBroad incumbents
- Syneos Health: Large biopharma-focused CRO (now PE-owned) offering clinical development and commercial services. Comparable on biopharma customer overlap and Phase II–IV positioning.
- Charles River Laboratories: Diversified CRO/CDMO spanning preclinical through clinical, with comparable specialty therapeutic focus and global footprint. Competes with Emmes for early-stage clinical and discovery-to-Phase II sponsor budgets.
- Parexel International: Large global CRO with strong specialty/biopharma focus and significant Phase I-IV capabilities. Comparable to Emmes on the biopharma customer base and therapeutic breadth, though materially larger and PE-owned (EQT/Goldman).
- Fortrea: Clinical CRO spun out of Labcorp in 2023, offering full-service Phase I-IV development with strong technology and biopharma franchise. Direct competitor on mid- and large-sized clinical CRO bids.
- ICON plc: Top-tier global CRO offering full-service clinical development including a strong technology and decentralized trial portfolio. Overlaps with Emmes on Phase I-IV biopharma services; Emmes's new CCO Germaine Gross is a former ICON BD leader.
- IQVIA: Largest global CRO with deep technology, real-world evidence, and commercial capabilities. Sets the competitive benchmark Emmes must beat on bundled biopharma programs and AI/data infrastructure investment.
Direct peers
- Clario: Technology-led clinical trial endpoint and eCOA/ePRO specialist offering software and scientific expertise for decentralized and hybrid trials. Highly comparable to Emmes's Veridix platform on eClinical and patient-facing data capture.
- Worldwide Clinical Trials: Privately held specialty CRO focused on complex therapeutic areas including rare disease, neuroscience, and oncology. Highly comparable to Emmes given similar mid-sized scale, specialty positioning, and private ownership structure.
- Medpace: Mid-sized, tech-forward full-service clinical CRO with strong organic growth model and proprietary technology stack. Closely comparable to Emmes in operating philosophy (specialty CRO with technology differentiation), though larger and publicly listed.
Emerging players
- Allucent: Mid-sized specialty CRO with particular strength in cell and gene therapy and rare disease — directly mirroring Emmes's VaxTrials and rare disease specialty focus, though smaller in scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
The Emmes Group social profiles
Digital presenceThe Emmes Group compliance and trust
Trust signalCompliance1 record
The Emmes Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
The Emmes Group leadership team
Management profileNumber of profiles
Profiles2 records
The Emmes Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The Emmes Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The Emmes Group
What does The Emmes Group do?
The Emmes Group is a full-service Contract Research Organization (CRO) delivering Phase I–IV clinical trial management across 90+ countries, supported by a proprietary AI-enabled technology platform (Veridix) that provides electronic data capture, randomization and supply management, eCOA/ePRO, decentralized clinical trials, global site tracking, and AI agents for biostatistics, data management, and document authoring. Specialty therapeutic expertise is delivered through dedicated brands for vaccines/infectious disease, ophthalmology, clinical neuroscience, rare disease, cell & gene therapy, and government health programs.
Is The Emmes Group a public or private company?
The Emmes Group is a private company. It is classified as unknown and is currently operating.
When was The Emmes Group founded?
The Emmes Group was founded in 1977. It employs 1,001 to 5,000 people.
Where is The Emmes Group based?
The Emmes Group is headquartered in Rockville, United States, in the North America region.
How does The Emmes Group make money?
One revenue line is on record: CRO Services.
Who are The Emmes Group's main competitors?
Broad incumbents on record are Syneos Health, Charles River Laboratories, Parexel International, Fortrea, ICON plc and IQVIA. Direct peers are Clario, Worldwide Clinical Trials and Medpace. Allucent is listed as an emerging player.
Does The Emmes Group have an API?
No public API is recorded for The Emmes Group.
What industry is The Emmes Group in?
The Emmes Group's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs. Its NAICS code is 5417 and its SIC code is 8731.